COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2022
Net Of Discount			$ 11,800,000
Research And Development Expenses			35,700,000
Increase In Right Of Use Asset And Liability			1,100,000
Operating Lease Right Of Use Assets	$ 1,700,000		1,700,000		$ 1,900,000
Operating Lease Liabilities	$ 1,900,000		$ 1,900,000		2,000,000.0
Weighted Average Discount Rate Operating Lease	10.20%		10.20%
Current portion of the operating lease obligation	$ 200,000		$ 200,000
Operating Lease Expense			300,000	$ 300,000.0
Operating Lease Payment			$ 300,000	200,000
Weighted Average Time To Maturity			7 years 11 months 8 days
Landlord [Member]
Interest Rate	8.45%		8.45%
Financing arrangement deposit base rent amount			$ 2,300,000
Financing arrangement deposit base rent percentage description			The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year
Financing Arrangement			$ 11,100,000
Payments Made By Landlord			$ 2,400,000
Transaction One [Member]
Weighted average maturity date of operating leases			5 years 4 months 2 days
Weighted Average Discount Rate	8.45%		8.45%
Net Book Value Of The Finance Lease Right Of Use Asset	$ 9,600,000		$ 9,600,000		10,900,000
Balance Of The Finance Lease Liability	12,100,000		12,100,000		$ 13,300,000
Cash Paid Related To Finance Leases			1,900,000	1,900,000.0
Cash Paid Related To Finance Leases Interest			800,000
Ergomed [Member]
Research And Development Expenses	$ 100,000	$ 100,000	100,000	$ 400,000
Clinical Service Trial			$ 12,000,000